Upcoming Financial Results and Corporate Update
Celcuity Inc. (NASDAQ: CELC), a pioneering clinical-stage biotechnology firm, is preparing to announce its financial results for the first quarter of 2025. This event is scheduled to take place shortly after the market closes on May 14, 2025. The leadership team will follow the announcement with a webcast and teleconference at 4:30 p.m. Eastern Time on the same day. This session aims to delve into the quarterly results and provide an insightful corporate update for stakeholders and interested parties.
Participating in the Event
To join the teleconference, domestic participants can call 1-800-717-1738, while international attendees are invited to dial 1-646-307-1865. Additionally, a live webcast of the event will be available, providing an accessible way for the broader audience to engage with the information shared. Following the live event, a replay will be made available on the official Celcuity website, allowing those who couldn’t attend to catch up on the crucial discussions.
About Celcuity Inc.
Celcuity is at the forefront of developing innovative targeted therapies aimed at treating various solid tumor indications. The company is chiefly recognized for its leading therapeutic candidate, gedatolisib. This potent compound acts as a dual inhibitor of the PI3K and mTOR pathways, effectively blocking the PI3K/AKT/mTOR (PAM) signaling pathway, which is crucial in cancer cell proliferation and survival. Gedatolisib’s unique mechanism sets it apart from existing treatments that might only target PI3K?, AKT, or mTORC1 component individually.
Clinical Studies and Ongoing Trials
One of the most exciting studies currently underway is the Phase 3 clinical trial, VIKTORIA-1. This trial is evaluating the effectiveness of gedatolisib in combination with fulvestrant, either alone or alongside palbociclib, among women suffering from HR+/HER2- advanced breast cancer. This promising trial is actively recruiting patients, showcasing Celcuity's commitment to advancing cancer care.
Further Research Initiatives
In addition to VIKTORIA-1, Celcuity is also conducting a Phase 1b/2 clinical trial, CELC-G-201. This study focuses on the combination of gedatolisib and darolutamide, specifically targeting patients battling metastatic castration-resistant prostate cancer. By diversifying its research, Celcuity is striving to meet the urgent needs of patients navigating aggressive cancer types.
Future Perspectives
As Celcuity continues to explore new frontiers in cancer therapies, there are plans for additional trials, including the Phase 3 VIKTORIA-2 trial. This study will further evaluate the combination of gedatolisib with a CDK4/6 inhibitor and fulvestrant as a first-line treatment option for patients with HR+/HER2- advanced breast cancer. The company’s relentless pursuit of innovative cancer therapies speaks volumes about its mission to provide effective treatment options.
Staying Connected with Celcuity
Celcuity is based in Minneapolis and is dedicated to building a future where targeted therapies can drastically improve the lives of cancer patients. For individuals looking to stay updated on Celcuity's advancements and clinical trials, the company encourages followers to visit their official website or engage with them on social media platforms, including LinkedIn and Twitter. Through these channels, Celcuity shares insights into their ongoing research and corporate news.
Frequently Asked Questions
What are the financial results that Celcuity is expected to announce?
Celcuity will reveal its Q1 financial results, offering insights into the company's performance and financial health within the biotech sector.
When will the webcast and teleconference take place?
The event is scheduled for May 14, 2025, at 4:30 p.m. Eastern Time, following the release of the financial results.
How can I participate in the teleconference?
To participate, domestic callers can dial 1-800-717-1738, and international callers should use 1-646-307-1865.
What is the focus of Celcuity's clinical trials?
Celcuity's trials primarily focus on the therapeutic effects of gedatolisib on various solid tumors, including advanced breast cancer and prostate cancer.
How can I stay updated on Celcuity's progress?
To keep informed about Celcuity's latest developments, visit their official website or follow them on LinkedIn and Twitter for the newest updates and news releases.
